Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > BUSINESS
BUSINESS
- Kyorin to Develop High-Speed PCR System for Coronavirus Detection, Eyes Launch by March-End
March 18, 2020
- Chugai Recalls Herceptin over Glass Contamination
March 18, 2020
- Shionogi Seeks Collaboration with Lab Test Service Provider on Coronavirus Antibody-Test Kit in Japan
March 18, 2020
- Pfizer Joining Fray in Japan AG Market with Celecox
March 17, 2020
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
- Shigeo Taniuchi to Become CEO of Santen
March 16, 2020
- Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
March 16, 2020
- Daicel, AnGes/Osaka Univ. to Collaborate in Developing COVID-19 Vaccine
March 16, 2020
- PeptiDream, Mitsubishi to Launch JV to Develop Peptide Alternatives to Cell Culture Growth Factors
March 16, 2020
- Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
March 13, 2020
- Medicago Successfully Produces COVID-19 Vaccine Candidate
March 13, 2020
- Sanofi Exploring Kevzara Use for Novel Coronavirus
March 13, 2020
- Pfizer Japan Delivers 1.1% Growth in FY2019
March 13, 2020
- Artz Battered by Deep Reduction as “G2” Price Cut Applied for Second Time
March 12, 2020
- Ninlaro Misses Primary Goal in Front-Line Myeloma Study
March 12, 2020
- Nipro Confirms Coronavirus Infection Case at Niigata Branch
March 12, 2020
- Shionogi Wins Osaka Tax Suit over ViiV Deal
March 12, 2020
- Santen Calls Off Development of wAMD Treatment after PIIa Fails
March 12, 2020
- Kowa’s Glaucoma Med Glanatec Approved in Singapore
March 12, 2020
- Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus
March 11, 2020
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…